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This editorial refers to ‘A CD36-dependent pathway
enhances macrophage and adipose tissue inflammation and
impairs insulin signalling’ by D.J. Kennedy et al., pp.
604–613, this issue.
Insulin resistance, a decreased metabolic responsiveness of peripheral
organs and tissues to insulin, is considered the central mechanism of
metabolic syndrome, a cluster of cardiovascular risk factors, including
abdominal obesity, hypertension, a pro-atherogenic lipid profile, a
pro-thrombotic, pro-inflammatory state, and dysglycemia. Studies in
recent years have revealed the causal role of chronic low-grade
inflammation in development of obesity-associated insulin resistance
in animal models.1 Since chronic inflammation also plays a pivotal
role in atherosclerotic cardiovascular disease,2 it is therefore con-
sidered to be the fundamental mechanistic link between insulin resist-
ance and increased cardiovascular prevalence in obesity. Compelling
evidence from numerous studies in animal models demonstrates
that monocytes are recruited to adipose tissue during obesity and
become macrophages through interaction with dysfunctional adipo-
cytes.3 Moreover, resident adipose tissue macrophages may switch
their phenotype from the anti-inflammatory ‘alternative’ (M2) to
pro-inflammatory ‘classical’ (M1) macrophages during expansion of
adipose tissue in obesity.4 Accumulation of macrophages and pheno-
typic switch from M2 to M1 macrophages has been suggested to play
a determinant role in insulin resistance in obesity at least in mouse
models.3 Increased adipose tissue inflammation and macrophage infil-
tration have been confirmed in human obesity.5 However, subset
macrophage accumulation in human adipose tissue in obesity requires
further characterization.
There is much interest in the question of what are the micro-
environmental changes in adipose tissue in obesity that initiate and
regulate adipose tissue inflammation. Adipocytes are highly active in
secretion of numerous bioactive hormones called adipokines that
exert profound endocrine and/or paracrine effects on different
types of cells including macrophages and vascular wall cells, i.e. endo-
thelial cells or smooth muscle cells.6 It is proposed that adipocyte dys-
function reflected by imbalanced secretion of pro-inflammatory and
anti-inflammatory adipokines contributes to insulin resistance,
metabolic disorders, and cardiovascular disease.6 Crosstalk between
perivascular adipocytes and the vascular wall or adipocytes and
macrophages through paracrine secretion of adipokines has been
reported in many studies in recent years.3 It has been demonstrated
that adipocytes or perivascular adipose tissues release relaxing
factors causing vascular smooth muscle relaxation, and secrete
smooth muscle cell growth inhibitors such as adiponectin as well as
growth promoters, which could play a role in vascular remodelling
under disease conditions.6,7 Moreover, increased perivascular
adipose tissue inflammatory cell infiltration in atherosclerosis has
also been demonstrated in patients,6 which is similar to the phenom-
enon in obesity. To what extent the perivascular adipose tissue
inflammation contributes to cardiovascular disease remains to be
determined. Also, regulatory mechanisms of crosstalk between adipo-
cytes and macrophages and other cells in obesity and cardiovascular
disease are largely unknown.
The study by Kennedy et al.8 explored the crucial role of CD36 in
mediating crosstalk between adipocytes and macrophages in vitro and
also in vivo in mouse models of obesity. CD36, first discovered in
platelets 30 years ago, is now characterized as a membrane glyco-
protein that is widely expressed on the surface of a variety of cell
types, including cardiomyocytes, vascular endothelial cells, smooth
muscle cells, macrophages, adipocytes, and hepatocytes.9 CD36 func-
tions as a class B scavenger receptor and fatty acid translocase that
binds long-chain fatty acids and facilitates their transport into cells.
CD36 also binds and scavenges a wide spectrum of endogenous mol-
ecules, including oxidized lipids from LDL, advanced glycated proteins,
components of apoptotic cells, and cell-derived microparticles.9 It
seems not surprising that the previous work of this research group
and others demonstrated multiple cellular functions of CD36.9,10
For example, CD36 functions as a negative regulator of angiogenesis
and promotes endothelial apoptosis; it promotes oxidative stress by
down-regulation of antioxidant enzymes peroxiredoxin-2 and haem
oxygenase-1 in vascular smooth muscle cells under conditions of vas-
cular injury; it renders platelets hypersensitive to aggregation stimuli
and thereby promotes platelet aggregation and secretion; it promotes
lipid uptake in macrophages and facilitates foam cell formation. It
appears that CD36-mediated effects on a variety of cell types are
through similar signal transduction pathways, i.e. activation of the non-
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receptor tyrosine kinase Src family (Fyn and Lyn) and the serine/
threonine kinase MAPK family (JNK and p38 MAPK).9
In this study, Kennedy et al.8 further demonstrated that CD36
deficiency in several backgrounds protects mice from chronic
adipose tissue inflammation induced by high fat diet (HFD) feeding.
Although obesity was protected in CD362/2 mice fed HFD when
compared with wild-type controls, no difference in body weight
was observed between ApoE2/2 and ApoE2/2/CD362/2 mice.
The results demonstrate a direct anti-inflammatory effect of CD36
deficiency that is independent of reduced obesity. The authors
further elucidated the underlying mechanisms involved in adipose
tissue inflammation and insulin resistance. By using several specific
genetic knockout mice and through analysing adipocyte–macrophage
interactions, they demonstrated that CD36 in adipocytes interacts
with Fyn and Lyn tyrosine kinases, resulting in JNK activation and
impaired insulin signalling. The dysfunctional adipocytes secrete adipo-
kines and thereby stimulate macrophage migration. On the other
hand, CD36 also impairs insulin signalling in macrophages from mice
fed HFD, resulting in enhanced production of pro-inflammatory cyto-
kines and reactive oxygen species accompanied by increased inducible
NO synthase expression and decreased arginase activity, which
resembles the M1 phenotype. Co-culture experiments further
showed that CD36-positive but not CD36-deficient macrophages
impair insulin signalling in adipocytes. The authors proposed a
model of crosstalk between adipocytes and macrophages through
CD36 to explain the protection against insulin resistance by CD36
deficiency (see Figure 6 in their published study8).
This study has shed new light on the role of CD36 in
obesity-associated inflammation that links obesity to increased risk
of atherosclerotic cardiovascular disease. It is of note that the contri-
bution of CD36 to insulin resistance as well as to atherosclerosis in
the literature is controversial. Both CD36-mediated contribution to
and CD36-mediated protection from insulin resistance have been
reported.9,11 The phenotype of CD36 deficiency seems also depen-
dent on the type of diet. It has been reported that in mice, CD36
deficiency enhances insulin responsiveness on a high starch, low-fat
diet, and it predisposes to insulin resistance induced by high fructose
diet.12 One should consider whether CD36 deficiency is indeed ben-
eficial or detrimental for the whole organism even under conditions
where a protective metabolic profile can be achieved. For example,
CD36 deficiency may be detrimental for the heart because fatty
acid uptake in cardiomyocytes, the major energy source for the
heart, is impaired. Indeed, a link between CD36 deficiency and hyper-
trophic cardiomyopathy in humans has been proposed.13 Another
important consideration is that if arginase activity were increased in
vascular endothelial cells by CD36 deficiency, as shown in this
study for adipose tissues or macrophages, the endothelial NO pro-
duction would be expected to decrease,14 which could also have a
negative impact on insulin sensitivity and cardiovascular function, as
endothelial dysfunction, i.e. decreased endothelial NO bioavailability,
plays a role in insulin resistance, obesity, and atherosclerosis.14
There is a report showing that CD36 is required for eNOS activation
by certain free fatty acids;15 however, whether these aspects could
partly explain the controversial results of CD36 deficiency on
insulin resistance and atherogenesis requires further investigation. In
addition, interaction of CD36 polymorphisms with other genetic
determinants could also affect the phenotypes.
Nevertheless, it appears that more recent studies support the ben-
eficial effects of CD36 deficiency on inflammation and metabolic
profile.9 More disease-associated endpoints such as heart function,
endothelial function, and survival rate would be required to determine
the final benefit of CD36 deficiency in obesity and atherosclerosis.
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